 NEW YORK, April 27, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced that data related to REL-1017, the companys lead product candidate, will be presented in a poster at the American Society for Pharmacology and Experimental Therapeutics ASPET Annual Meeting at Experimental Biology EB 2021, which is being held virtually between April 27 and April 30, 2021. Details of the presentation are below: Poster Number: R2195 Title: REL-1017 esmethadone Did Not Produce Initial or Cumulative Neurotoxic Effects or Other Evidence of Damage to Cortical Neurons The abstract is available on the meeting website and the poster is also available online to registered attendees from April 13 to May 31, 2021. 